Written and clinically reviewed by Jeremy Swisher, MD
Start here
A symptom-management option, not a cartilage cure.
Hyaluronic acid, also called viscosupplementation, is injected into the knee joint with the goal of temporarily improving pain and function. It is usually considered after exercise-based care and other appropriate options have not provided enough relief.
Goal
Improve symptoms enough to support walking, stairs, exercise, sleep, or another defined activity.
Timing
When benefit occurs, it often builds over several weeks rather than immediately.
Limit
It has not been shown to regrow cartilage, reverse arthritis, or reliably prevent knee replacement.
Current evidence
The average added benefit is small, but averages do not tell the whole story.
Large evidence reviews find that saline injection groups also improve substantially and that the average additional pain relief from hyaluronic acid is often modest. Some individual patients still report meaningful improvement lasting several months.
When benefit occurs, it commonly emerges over several weeks and may last for several months. Response and duration vary, and benefit appears less favorable in end-stage osteoarthritis.
Group average
The added benefit over saline is usually small and may fall below common thresholds for clinical importance.
Who is likely to respond?
A subgroup may obtain worthwhile relief, but current tests cannot reliably identify that person in advance.
Practical meaning
Consider expected benefit, low systemic exposure, inconvenience, cost, alternatives, and the chance of no response.
Why saline-controlled injection trials are difficult to interpret
People in saline injection groups can improve because of the injection procedure and surrounding care, even when the injected fluid is inactive. Study quality, product type, injection schedule, disease severity, and the definition of a “responder” can all change the conclusion.
Guideline context
Professional recommendations do not agree.
The disagreement reflects different evidence dates, risk-of-bias standards, outcome definitions, patient profiles, products, and thresholds for what counts as worthwhile benefit.
- 01
American Academy of Orthopaedic Surgeons (AAOS), 2021
Does not recommend hyaluronic acid for routine use. Its evidence discussion still recognizes that some carefully selected people may benefit.
- 02
American College of Rheumatology and Arthritis Foundation (ACR/AF), 2019
Conditionally recommends against it for knee osteoarthritis because benefit approached zero in lower-risk-of-bias trials, while preserving shared decision-making after other options fail.
- 03
U.S. Department of Veterans Affairs and Department of Defense (VA/DoD), 2026
Finds insufficient evidence to recommend for or against hyaluronic acid after other interventions fail. This supersedes the more favorable 2020 recommendation.
- 04
Osteoarthritis Research Society International (OARSI), 2019, and American Medical Society for Sports Medicine (AMSSM), 2016
Allow or support selective use for knee osteoarthritis in defined patient groups. These recommendations are more favorable than AAOS and ACR.
How to use this disagreement
“Not routine” is not the same as “never.”
Hyaluronic acid should not replace foundational care or be presented as predictably effective. It can still be discussed selectively when symptoms persist, other options are unsuitable or inadequate, and the patient understands the uncertainty.
Patient selection
Who may reasonably consider it?
Best supported by evidence
Confirmed symptomatic knee osteoarthritis, often mild to moderate, with persistent activity limits despite structured exercise and rehabilitation.
Why consider it
Other appropriate treatments gave inadequate relief, caused side effects, or are limited by your medical history.
Pause or defer
Fever, infection, a hot, unexplained swollen knee, major diagnostic uncertainty, relevant product allergy, or planned knee replacement without coordinated timing.
End-stage disease is not an absolute contraindication, but the chance of meaningful improvement appears lower and expectations should be especially guarded.
Define success before treatment
Choose a measurable goal such as walking farther, climbing stairs with less pain, sleeping better, or returning to a specific activity. If there is no meaningful improvement after an adequate observation period, repeating the same treatment is unlikely to help.
Product selection
Hyaluronic acid is a class, not one uniform injection.
Products differ in molecular weight, crosslinking, source, concentration, injected volume, and whether treatment uses one or several visits. Those differences do not reliably predict who will improve.
- Molecular weight. Some analyses favor higher-molecular-weight products, but direct comparisons do not establish one category as universally superior.
- Crosslinking. It changes product properties and may influence local reactions, but does not guarantee better pain relief.
- Source. Some products are avian-derived and others use bacterial fermentation. Allergy history can affect selection.
- Schedule. Product labeling may call for one to five injections. A single injection is more convenient, not automatically stronger or more effective.
Selection should consider evidence, allergy history, visit burden, availability, product labeling, and insurance coverage. The exact product should be known before treatment.
Before, during, and after
What to expect from treatment.
- 01
Confirm the diagnosis and goal
Review symptoms, examination, weight-bearing X-rays when appropriate, prior care, and the activity that treatment is meant to improve.
- 02
Review the product and safety plan
Discuss allergies, medications, recent injections, infection risk, knee swelling, surgical plans, product source, schedule, cost, and authorization.
- 03
Perform a sterile joint injection
Ultrasound may improve placement accuracy, identify fluid, and guide aspiration when needed. It is helpful in selected cases but is not mandatory for every knee.
- 04
Track response over time
Follow the care team's activity instructions and assess the predefined functional goal over roughly six to twelve weeks rather than judging the result immediately.
After the injection
Temporary pain, swelling, warmth, stiffness, or brief worsening can occur. Product-specific instructions vary. For some products, limiting strenuous or prolonged weight-bearing activity for about 48 hours is advised.
When to seek urgent assessment
Seek same-day urgent medical assessment and contact the injecting team for rapidly increasing pain or swelling, marked warmth or redness, fever, drainage, inability to bear weight, or symptoms that continue to worsen. Do not wait for a routine reply. Call 911 if you are severely ill, faint, confused, have trouble breathing, or have another medical emergency. Infection and a severe sterile inflammatory reaction can look alike and may require examination and joint-fluid testing.
Coverage and timing
Confirm the practical details before scheduling.
Coverage varies by insurer, product, and location. Plans may require recent X-rays, documentation of conservative treatment, a specific product, prior authorization, or proof of meaningful benefit before a repeat series. Ultrasound guidance may be billed separately.
Tell both the injecting clinician and surgeon if knee replacement is being considered. Observational studies have reported possible infection risk when injections are given close to surgery, but the exact interval is not universally settled. The treating surgeon should guide timing.
- Confirm the product, number of visits, copay, and authorization requirements.
- Ask how repeat-treatment rules apply and whether a minimum interval is required.
- Bring recent knee images and reports, including actual images when available.
- Share any knee replacement plans so injection timing can be coordinated.
Compare options
No injection replaces foundational care.
Hyaluronic acid
A non-steroid option with gradual and variable benefit. Often covered only after specific plan criteria are met.
PRP
Made from your own blood and biologically variable. Evidence is evolving, product characterization and total platelet dose may matter, and insurance coverage is often limited.
Corticosteroid
May provide faster short-term relief, with different health risks and considerations around repeat use.
Exercise, rehabilitation, activity planning, and other appropriate health strategies remain the foundation. The right choice may be another injection, no injection, or a surgical consultation.
For PTs & referring clinicians
Judge response by a predefined functional outcome.
Useful referral information includes the working diagnosis, radiographic severity, symptom behavior, rehabilitation dose and response, objective progress, prior injections, medical constraints, and the function treatment is intended to improve. Rehabilitation should continue around any procedure.
UCLA referral informationCommon questions
Hyaluronic acid FAQs
Why do some guidelines recommend against hyaluronic acid?
In the highest-quality placebo-controlled trials, the average added benefit is often small. Guidelines weigh that finding, cost, product variability, safety, and responder analyses differently. Some discourage routine use, while others allow selective use.
How quickly can it work?
It is not an immediate pain reliever. When benefit occurs, it commonly develops over several weeks and may last for several months, but response and duration vary.
Is one injection better than a series?
No schedule is best for every patient. Product labeling ranges from one to five injections, and some direct studies find similar outcomes between schedules. Convenience, evidence, coverage, and product choice all matter.
Can it be repeated?
A repeat course should usually require meaningful benefit from the prior course, recurrence of symptoms, an appropriate interval, and continued fit with the broader plan. It should not be repeated automatically after nonresponse.
Can I schedule the injection directly?
Call UCLA Orthopedics to arrange an evaluation with Dr. Swisher. Diagnosis, candidacy, product availability, authorization, cost, and procedure timing must be reviewed first, so an injection is not guaranteed at the initial visit.
Evidence
Sources and further reading
These sources reflect both favorable and unfavorable interpretations of hyaluronic acid for knee osteoarthritis.
- AAOS: Management of Osteoarthritis of the Knee, Third Edition, 2021
- American College of Rheumatology / Arthritis Foundation Osteoarthritis Guideline
- VA/DoD: Non-Surgical Management of Hip and Knee Osteoarthritis, 2026
- OARSI Guidelines for Non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis, 2019
- AMSSM Scientific Statement on Viscosupplementation for Knee Osteoarthritis, 2016
- NICE: Osteoarthritis in Over 16s Recommendations, 2022
- ESCEO Updated Treatment Algorithm for Knee Osteoarthritis, 2019
- BMJ: Viscosupplementation for Knee Osteoarthritis Systematic Review and Meta-analysis, 2022
- Comparison of Hyaluronic Acid Molecular Weights: Bayesian Network Meta-analysis, 2025
- CHASE Trial: One-Injection Versus Five-Injection Hyaluronic Acid Regimens, 2015
- Ultrasound-Guided Versus Landmark-Guided Knee Injection Accuracy Trial, 2012
- CMS: Hyaluronan Acid Therapies for Osteoarthritis of the Knee Coverage Policy
Evidence and coverage policies can change. This page is educational and does not establish whether hyaluronic acid is appropriate or covered for a particular patient.